Low Dose Naltrexone for Multiple Sclerosis

People suffering from multiple sclerosis are still hoping that a cure may someday be discovered that would ultimately get rid of their lifelong ailment. Multiple sclerosis can really be a condition that can limit one’s capabilities to enjoy life. What most sufferers hope for today is find an effective multiple sclerosis treatment that would help control or lessen the symptoms associated with the disease that affect them on a regular basis.

Types of multiple sclerosis treatment

There are many types of multiple sclerosis treatments that doctors prescribe for different forms of the disease. One of the emerging treatments that people believe will help multiple sclerosis patients is the use of low dose naltrexone therapy. But this type of therapy is still considered as an off label therapy for lack of proper studies made to prove its effectiveness on multiple sclerosis.

The use of Naltrexone is actually already been approved for use by the FDA. But its use wasn’t targeted as therapy for people afflicted with multiple sclerosis. Naltrexone is mainly used for treatment of alcohol and opoid drug dependence. But the use of low dose naltrexone therapy has recently been seen to have beneficial effects for treating autoimmune diseases such as multiple sclerosis as well as other types of cancers.

How low dose of naltrexone work?

LDN believe to work in several ways in trying to treat certain ailments. Without formal studies yet being conducted, a formal conclusion has yet to be reached as to how this form of therapy really works. But most proponents of the therapy believe that naltrexone causes a blockage of the endorphin receptors in the brain. Endorphins allow drug users to derive pleasure from the effects of the drug.

By providing an effective blockade, drug users are therefore prevented from getting the usual pleasure from drug use and therefore break their dependence from it. Instead of the normal dose used to treat drug and alcohol dependence in patients, treating autoimmune diseases such as multiple sclerosis requires just a low dose of the compound, usually from 3 to 5 mg.

The low dose of naltrexone seems to block a number of endorphin receptors from attaching to the endorphins. But because there is a shortage of receptors, it triggers the body to create more endorphins. Once the low dose of naltrexone is metabolized in the body, it is left with a normal amount of endorphins which eventually normalizes the immune function.

The LDN therapy is seen to be quite controversial by some in that it contradicts the normally held belief that autoimmune diseases such as multiple sclerosis are being caused by an overactive immune system.